Integrated BioPharma extends PNC Bank revolving credit line to April 2027, keeps USD 4 million limit
PNC Financial Services Group, Inc. PNC | 0.00 | |
INTEGRATED BIOPHARMA INC INBP | 0.00 |
- Integrated BioPharma amended its loan documents with PNC Bank, extending the committed revolving credit facility maturity to April 14, 2027.
- The revolving line remains capped at USD 4 million outstanding.
- The borrower also added a USD 250,000 Convertible Line of Credit Note (Daily SOFR) to fund equipment or vehicle purchases.
- Before conversion, the Convertible ELOC rate is daily one-month SOFR + 2.5%; post-conversion it stays floating or shifts to a bank-offered fixed rate.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Integrated BioPharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-022415), on July 02, 2026, and is solely responsible for the information contained therein.
